title: Leflunomide: a new DMARD for rheumatoid arthritis.
abstract: Early diagnosis and referral of rheumatoid arthritis may significantly improve patient outcomes. Arava (leflunomide) is the first new disease modifying antirheumatic drug (DMARD) to be introduced in the UK for over a decade. Arava has a rapid onset of action and has been shown to retard radiographic disease progression and significantly improve patients' functional ability.
authors.affiliation: Rheumatology and Rehabilitation Research Unit, University of Leeds.
authors.forename: P
authors.initials: P
authors.lastname: Emery
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D008297:Male; D008875:Middle Aged
chemical_list: D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D007555:Isoxazoles; D000077339:Leflunomide